Orphan Drug Approvals — July 18, 2026
During July 18, 2026, the FDA issued two label expansion approvals for SELPERCATINIB (RETEVMO) by ELI LILLY AND CO, classified as 'Other' with no NME, biosimilar, or standard label expansion mix. Both approvals carry a bullish signal with moderate strength and materiality, suggesting incremental commercial value for LILLY's RETEVMO franchise, though specific indication details and peak sales estimates are NOT_DISCLOSED. The lack of NME or biosimilar approvals in this period limits sector-level innovation signals, but the dual approval for the same drug on the same day may indicate a strategic push to broaden label utility. The highest-conviction signal is the label expansion for SELPERCATINIB, which could support LILLY's oncology portfolio, but absence of disclosed clinical or market detail tempers conviction. Key risks include any potential confirmatory trial requirements or competitive pressure from other RET inhibitors like LOXO-292 in the RET-altered tumor landscape.